Aura Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-78.65	-76.41	-58.76	-46.19	-30.13	-30.23
Depreciation & Amortization	3.46	3.13	2.15	0.83	0.83	0.51
Share-Based Compensation	9.77	8.77	6.41	2.31	0.74	0.51
Other Operating Activities	-6.47	0.66	-4.4	10.65	-3.68	2.52
Operating Cash Flow	-71.89	-63.85	-54.6	-32.41	-24.32	-20.67
Capital Expenditures	-0.69	-0.71	-1.09	-2.13	-0.77	-2.22
Change in Investments	-37	-113.25	-66.78	0	0	0
Investing Cash Flow	-37.69	-113.96	-67.87	-2.13	-0.77	-2.22
Share Issuance / Repurchase	97.34	97.29	95.63	79.05	0.16	0.06
Debt Issued / Paid	0	0	0	0	0	-0.04
Other Financing Activities	-	-	-	87.21	9.87	39.71
Financing Cash Flow	97.34	97.29	95.63	166.26	10.04	39.73
Net Cash Flow	-12.23	-80.52	-26.84	131.72	-15.06	16.84
Free Cash Flow	-72.58	-64.56	-55.7	-34.54	-25.09	-22.89
Free Cash Flow Per Share	-1.47	-1.63	-1.86	-6.69	-68.33	-4.94

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).